ES2536880T3 - Compuestos de purina - Google Patents

Compuestos de purina Download PDF

Info

Publication number
ES2536880T3
ES2536880T3 ES09768474.0T ES09768474T ES2536880T3 ES 2536880 T3 ES2536880 T3 ES 2536880T3 ES 09768474 T ES09768474 T ES 09768474T ES 2536880 T3 ES2536880 T3 ES 2536880T3
Authority
ES
Spain
Prior art keywords
methyl
chloro
tetrahydro
purine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09768474.0T
Other languages
English (en)
Spanish (es)
Inventor
Peter Charles Astles
Rossella Guidetti
Sean Patrick Hollinshead
Michael Wade Tidwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2536880T3 publication Critical patent/ES2536880T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES09768474.0T 2008-12-18 2009-12-09 Compuestos de purina Active ES2536880T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18
US138589P 2008-12-18
PCT/US2009/067249 WO2010080306A1 (en) 2008-12-18 2009-12-09 Purine compounds

Publications (1)

Publication Number Publication Date
ES2536880T3 true ES2536880T3 (es) 2015-05-29

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09768474.0T Active ES2536880T3 (es) 2008-12-18 2009-12-09 Compuestos de purina

Country Status (29)

Country Link
US (1) US8252798B2 (enExample)
EP (1) EP2379555B1 (enExample)
JP (1) JP5559812B2 (enExample)
KR (1) KR101319630B1 (enExample)
CN (1) CN102256977B (enExample)
AR (1) AR075104A1 (enExample)
AU (1) AU2009335997B2 (enExample)
BR (1) BRPI0923195A2 (enExample)
CA (1) CA2746740C (enExample)
CL (1) CL2011001464A1 (enExample)
CO (1) CO6390101A2 (enExample)
CR (1) CR20110340A (enExample)
DO (1) DOP2011000196A (enExample)
EA (1) EA018386B1 (enExample)
EC (1) ECSP11011151A (enExample)
ES (1) ES2536880T3 (enExample)
HN (1) HN2011001700A (enExample)
IL (1) IL213167A (enExample)
MA (1) MA32904B1 (enExample)
MX (1) MX2011006442A (enExample)
NZ (1) NZ593088A (enExample)
PA (1) PA8851501A1 (enExample)
PE (1) PE20110999A1 (enExample)
SG (1) SG172253A1 (enExample)
TN (1) TN2011000291A1 (enExample)
TW (1) TWI376378B (enExample)
UA (1) UA104010C2 (enExample)
WO (1) WO2010080306A1 (enExample)
ZA (1) ZA201103943B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543216T3 (es) * 2009-03-13 2015-08-17 Katholieke Universiteit Leuven, K.U. Leuven R&D Moduladores de tiazolopirimidina como agentes inmunosupresores
KR20200008045A (ko) 2009-08-28 2020-01-22 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
RU2012141536A (ru) * 2010-03-17 2014-04-27 Ф. Хоффманн-Ля Рош Аг Имидазопиридины, композиции и способы применения
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
KR101432411B1 (ko) * 2010-03-31 2014-08-20 일라이 릴리 앤드 캄파니 Ｃｂ2 효능제로서 사용되는 퓨린 화합물
CN103209695A (zh) 2010-09-15 2013-07-17 弗·哈夫曼-拉罗切有限公司 氮杂苯并噻唑化合物、组合物及应用方法
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
JP6043733B2 (ja) 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ， インコーポレイテッド カンナビノイド受容体モジュレーター
MX346533B (es) 2011-02-25 2017-03-14 Arena Pharm Inc Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2013041539A1 (en) * 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
PH12015500315B1 (en) * 2012-08-16 2019-08-07 Janssen Pharmaceutica Nv Substituted pyrozales as n-type calcium channel blockers
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
HRP20171099T1 (hr) * 2013-05-02 2017-10-06 F. Hoffmann - La Roche Ag Derivati pirolo[2,3-d]pirimidina kao agonisti cb2 receptora
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2018137176A1 (en) * 2017-01-25 2018-08-02 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017184412A1 (en) 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
JP7071342B6 (ja) * 2016-12-21 2023-12-20 リサーチ トライアングル インスティテュート 改善されたバイオアベイラビリティを有するジアリールプリン誘導体
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2024017227A1 (zh) * 2022-07-21 2024-01-25 长春金赛药业有限责任公司 取代的稠环大麻素受体化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
IL87149A (en) 1987-07-20 1994-05-30 Merck & Co Inc 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005067546A2 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
KR20070054737A (ko) * 2004-10-22 2007-05-29 화이자 프로덕츠 인코포레이티드 퓨린 화합물의 제조 방법
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
JP5231251B2 (ja) * 2006-02-02 2013-07-10 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
US20120295915A1 (en) * 2009-11-24 2012-11-22 Chaudhari Amita M Azabenzimidazoles as fatty acid synthase inhibitors
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Also Published As

Publication number Publication date
IL213167A0 (en) 2011-07-31
AU2009335997A1 (en) 2011-06-23
TN2011000291A1 (en) 2012-12-17
TW201024296A (en) 2010-07-01
CA2746740C (en) 2014-01-14
EA018386B1 (ru) 2013-07-30
CO6390101A2 (es) 2012-02-29
JP2012512873A (ja) 2012-06-07
CN102256977B (zh) 2014-04-16
CA2746740A1 (en) 2010-07-15
NZ593088A (en) 2012-12-21
US8252798B2 (en) 2012-08-28
US20100160288A1 (en) 2010-06-24
CL2011001464A1 (es) 2012-01-20
AR075104A1 (es) 2011-03-09
IL213167A (en) 2013-11-28
UA104010C2 (en) 2013-12-25
KR101319630B1 (ko) 2013-10-17
SG172253A1 (en) 2011-07-28
AU2009335997B2 (en) 2012-05-10
WO2010080306A1 (en) 2010-07-15
KR20110084459A (ko) 2011-07-22
CN102256977A (zh) 2011-11-23
ECSP11011151A (es) 2011-07-29
EP2379555B1 (en) 2015-02-25
JP5559812B2 (ja) 2014-07-23
PE20110999A1 (es) 2012-01-16
TWI376378B (en) 2012-11-11
CR20110340A (es) 2011-09-16
BRPI0923195A2 (pt) 2016-02-16
PA8851501A1 (es) 2010-07-27
HN2011001700A (es) 2013-05-06
MA32904B1 (fr) 2011-12-01
MX2011006442A (es) 2011-07-19
EP2379555A1 (en) 2011-10-26
ZA201103943B (en) 2012-11-28
EA201170832A1 (ru) 2011-12-30
DOP2011000196A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
ES2536880T3 (es) Compuestos de purina
EP1532148B1 (en) Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity
ES2365960B1 (es) Nuevos antagonistas de los receptores de adenosina.
CN101072779B (zh) 2,4(4,6)嘧啶衍生物
KR20070033962A (ko) 증식성 질병의 치료에서 9ｈ-퓨린-2,6-디아민 유도체의용도 및 신규 9ｈ-퓨린-2,6-디아민 유도체
CA2673965A1 (en) Pyrazolopyrimidine compound
NZ720178A (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
CN104540809A (zh) 成纤维细胞生长因子受体的抑制剂
KR20110067038A (ko) 모르폴리노퓨린 유도체
US8759360B2 (en) Purine compounds
Gibson et al. The synthesis of 7-deazaguanines as potential inhibitors of guanosine triphosphate cyclohydrolase I
ES2481867T3 (es) Compuestos de purina usados como agonistas de CB2
Zhang et al. Synthesis of 2-Chloro-4-(3-Nitrophenoxy)-6-(Thiophen-2-Yl) Pyrimidine